Abstract
The CD30 antigen is strongly expressed on neoplastic cells in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL) and other hematologic malignancies (such as DLBCL and cutaneous TCL), while is almost undetectable on healthy tissues, representing an ideal immunotherapeutic target. Since unconjugated anti-CD30 antibody (SGN-30) demonstrated limited clinical activity, researchers’ effort aimed to create an antibody-drug conjugate (ADC), leading to discovery of SGN-35 (brentuximab vedotin), in which an anti-CD30 antibody is linked to the antimitotic agent monomethyl auristatin E (MMAE). In the first phase I study in CD30+ hematologic malignancies (the majority of patients with HL), the maximum tolerated dose was fixed respectively at 1.8mg/Kg every 3 weeks, overall response rate (ORR) and complete response (CR) rate were 38% and 24%. In 2 subsequent phase II studies, amazing results were reported, that permitted accelerated FDA approval for relapsed/refractory patients and led to the development of many clinical trials including BV as first-line HL and ALCL treatment. Moreover, as CD30 antigen may be expressed by other malignancies, the potential therapeutic application is increasing, including at least diffuse large B-cell lymphoma, T-cell lymphomas other than ALCL and cutaneous lymphoproliferative disorders. BV is administrated as outpatient regimen and is usually well tolerated; sensorial peripheral neuropathy represents the most common toxic effect, although it is dose-dependent and at least partially reversible in most cases, after dose reduction and/or treatment ending.
Keywords: Hodgkin lymphomas, anaplastic large cell lymphoma, therapy, brentuximab, vedotin, therapeutic.
Anti-Cancer Agents in Medicinal Chemistry
Title:Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Volume: 17 Issue: 7
Author(s): Alberto Fabbri*, Emanuele Cencini, Alessandro Gozzetti, Luana Schiattone and Monica Bocchia
Affiliation:
- Division of Hematology, University of Siena, Siena,Italy
Keywords: Hodgkin lymphomas, anaplastic large cell lymphoma, therapy, brentuximab, vedotin, therapeutic.
Abstract: The CD30 antigen is strongly expressed on neoplastic cells in classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL) and other hematologic malignancies (such as DLBCL and cutaneous TCL), while is almost undetectable on healthy tissues, representing an ideal immunotherapeutic target. Since unconjugated anti-CD30 antibody (SGN-30) demonstrated limited clinical activity, researchers’ effort aimed to create an antibody-drug conjugate (ADC), leading to discovery of SGN-35 (brentuximab vedotin), in which an anti-CD30 antibody is linked to the antimitotic agent monomethyl auristatin E (MMAE). In the first phase I study in CD30+ hematologic malignancies (the majority of patients with HL), the maximum tolerated dose was fixed respectively at 1.8mg/Kg every 3 weeks, overall response rate (ORR) and complete response (CR) rate were 38% and 24%. In 2 subsequent phase II studies, amazing results were reported, that permitted accelerated FDA approval for relapsed/refractory patients and led to the development of many clinical trials including BV as first-line HL and ALCL treatment. Moreover, as CD30 antigen may be expressed by other malignancies, the potential therapeutic application is increasing, including at least diffuse large B-cell lymphoma, T-cell lymphomas other than ALCL and cutaneous lymphoproliferative disorders. BV is administrated as outpatient regimen and is usually well tolerated; sensorial peripheral neuropathy represents the most common toxic effect, although it is dose-dependent and at least partially reversible in most cases, after dose reduction and/or treatment ending.
Export Options
About this article
Cite this article as:
Fabbri Alberto*, Cencini Emanuele, Gozzetti Alessandro, Schiattone Luana and Bocchia Monica, Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies, Anti-Cancer Agents in Medicinal Chemistry 2017; 17 (7) . https://dx.doi.org/10.2174/1871520616666160902100506
DOI https://dx.doi.org/10.2174/1871520616666160902100506 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Advances in Nanomedicines and Targeted Therapies for Colorectal Cancer
Colorectal cancer remains a significant global health challenge, with high incidence and mortality rates despite advancements in treatment strategies. Conventional therapies often face limitations such as systemic toxicity, drug resistance, and suboptimal targeting. The advent of nanomedicines and innovative drug delivery systems offers new hope for overcoming these challenges and ...read more
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Analysis of Drug Transport Kinetics in Multidrug-resistant Cells: Implications for Drug Action
Current Medicinal Chemistry Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
Current Topics in Medicinal Chemistry Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenetic Aspects of Drug Metabolizing Enzymes in Busulfan Based Conditioning Prior to Allogenic Hematopoietic Stem Cell Transplantation in Children
Current Drug Metabolism Antiviral Drugs in the Prophylaxis of HBV Infection
Current Medicinal Chemistry Protein Geranylgeranyltransferase Type 1 as a Target in Cancer
Current Cancer Drug Targets New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia
Current Cancer Drug Targets Novel Treatment of Acute Promyelocytic Leukemia: As<sub>2</sub>O<sub>3</sub>, Retinoic Acid and Retinoid Pharmacology
Current Pharmaceutical Biotechnology Subject Index
Current Drug Targets - Inflammation & Allergy Clinical Development of Inhibitors of the Insulin-like Growth Factor Receptor in Oncology
Current Drug Targets Immunomodulatory Drugs: Immune Checkpoint Agents in Acute Leukemia
Current Drug Targets Germinal and Somatic Trisomy 21 Mosaicism: How Common is it, What are the Implications for Individual Carriers and How Does it Come About?
Current Genomics Heat Shock Proteins: A Potential Anticancer Target
Current Drug Targets Study of Intercellular Adhesion Molecule-1 (ICAM-1) in Bone Homeostasis
Current Drug Targets MicroRNAs in Leukemias: Emerging Diagnostic Tools and Therapeutic Targets
Current Drug Targets Exploring Old Drugs for the Treatment of Hematological Malignancies
Current Medicinal Chemistry “Changing trends of Candidemia and antifungal susceptibility pattern in a tertiary health care centre:”
Infectious Disorders - Drug Targets Recent Approaches to Improve the Antitumor Efficacy of Temozolomide
Current Medicinal Chemistry Multimodal Imaging for the Diagnosis of Massive Left Atrial Metastasis from Lung Cancer - A Case Report
Current Medical Imaging Synthetic and Natural Immunomodulators Acting as Interferon Inducers
Current Pharmaceutical Design